Brain Tumor Pathology

, Volume 32, Issue 4, pp 237–244 | Cite as

Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies

  • Hayato Ikota
  • Sumihito Nobusawa
  • Hideo Arai
  • Yukinari Kato
  • Keisuke Ishizawa
  • Takanori Hirose
  • Hideaki Yokoo
Original Article


Glioma cells with the isocitrate dehydrogenase (IDH) 1 G395A mutation are strongly immunopositive for mIDH1R132H, an antibody against mutant IDH1R132H (clone H09). However, we encountered some gliomas which were ambiguously positive for mIDH1R132H despite having the IDH1 G395A mutation. The aim of this study was to establish an evaluation procedure of IDH1 status by immunohistochemistry. Forty-three diffusely infiltrating gliomas were studied, and four of eight anaplastic oligoastrocytomas with the IDH1 G395A mutation were modestly or weakly positive for both the mIDH1R132H and an antibody against wild type IDH1, RcMab-1. Based on our staining results, the IDH1 expression of both wild and mutated types seemed to be codominant and also to be evenly suppressed under a certain condition. We propose a procedure for determining IDH1 status. If a glioma is weakly positive for mIDH1R132H, immunohistochemistry for RcMab-1 should be performed. If the tumor cells are strongly positive for RcMab-1, the IDH1 G395A mutation is judged to be absent on the grounds that IDH1 expression is not suppressed. If the tumor cells are weakly positive for both mIDH1R132H and RcMab-1, then a conclusion should be made after DNA sequencing. This procedure is useful for practical evaluation of IDH1 status.


Glioma IDH1 Immunohistochemistry 



We thank Mr. Koji Isoda and Mr. Yu Otaki (Gunma University) for their excellent technical assistance. This work was supported in part by Platform for Drug Discovery, Informatics, and Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Y.K.), and a Grant-in-Aid for Young Scientists (B) (No. 24790346) from the Japan Society for the Promotion of Science (to H.I.).

Conflict of interest

The authors have no conflict of interest.


  1. 1.
    Ichimura K (2012) Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathol 29:131–139CrossRefPubMedGoogle Scholar
  2. 2.
    Reitman ZJ, Yan H (2010) Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102:932–941PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Zhao S, Lin Y, Xu W et al (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324:261–265PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Noushmehr H, Weisenberger D, Diefes K (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510–522PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Xu W, Yang H, Liu Y et al (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17–30PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Arita H, Narita Y, Yoshida A et al (2015) IDH1/2 mutation detection in gliomas. Brain Tumor Pathol 32:79–89CrossRefPubMedGoogle Scholar
  8. 8.
    Capper D, Zentgraf H, Balss J et al (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599–601CrossRefPubMedGoogle Scholar
  9. 9.
    Kato Y, Jin G, Kuan C-T et al (2009) A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 390:547–551PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Ikota H, Nobusawa S, Tanaka Y et al (2011) High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein. Brain Tumor Pathol 28:107–114CrossRefPubMedGoogle Scholar
  11. 11.
    Rohle D, Popovici-Muller J, Palaskas N et al (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340:626–630PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Wang F, Travins J, DeLaBarre B et al (2013) Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340:622–626CrossRefPubMedGoogle Scholar
  13. 13.
    Schumacher T, Bunse L, Pusch S et al (2014) A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512:324–327CrossRefPubMedGoogle Scholar
  14. 14.
    Ishizawa K, Hirose T, Sugiyama K et al (2012) Pathologic diversity of glioneuronal tumor with neuropil-like islands: a histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases. Clin Neuropathol 31:67–76CrossRefPubMedGoogle Scholar
  15. 15.
    Hirose T, Nobusawa S, Nakazato Y, Sasaki A (2013) A case of oligodendroglioma with prominent neuronal differentiation. Hum Pathol 44:2353–2359CrossRefPubMedGoogle Scholar
  16. 16.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system. IARC Press, LyonGoogle Scholar
  17. 17.
    Capper D, Weissert S, Balss J et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245–254CrossRefPubMedGoogle Scholar
  18. 18.
    Kaneko MK, Tsujimoto Y, Hozumi Y et al (2013) Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations. Monoclon Antib Immunodiagn Immunother 32:224–228CrossRefPubMedGoogle Scholar
  19. 19.
    Kato Y, Natsume A, Kaneko MK (2013) A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation. Biochem Biophys Res Commun 432:564–567CrossRefPubMedGoogle Scholar
  20. 20.
    Ohgaki H, Dessen P, Jourde B et al (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64(19):6892–6899CrossRefPubMedGoogle Scholar
  21. 21.
    Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Kato Y (2014) Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. Brain Tumor Pathol 32:3–11CrossRefPubMedGoogle Scholar
  23. 23.
    Takano S, Kato Y, Yamamoto T et al (2012) Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J Neurooncol 108:361–373CrossRefPubMedGoogle Scholar
  24. 24.
    Takano S, Tian W, Matsuda M et al (2011) Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 28:115–123CrossRefPubMedGoogle Scholar

Copyright information

© The Japan Society of Brain Tumor Pathology 2015

Authors and Affiliations

  • Hayato Ikota
    • 1
  • Sumihito Nobusawa
    • 1
  • Hideo Arai
    • 2
  • Yukinari Kato
    • 3
  • Keisuke Ishizawa
    • 4
  • Takanori Hirose
    • 5
  • Hideaki Yokoo
    • 1
  1. 1.Department of Human PathologyGunma University Graduate School of MedicineMaebashiJapan
  2. 2.Department of Diagnostic PathologyGunma University HospitalMaebashiJapan
  3. 3.Department of Regional InnovationTohoku University Graduate School of MedicineSendaiJapan
  4. 4.Department of PathologySaitama Medical UniversitySaitamaJapan
  5. 5.Department of Pathology for Regional CommunicationKobe UniversityKobeJapan

Personalised recommendations